Sodium–potassium–chloride cotransporter (NKCC)

The **sodium–potassium–chloride cotransporter** (NKCC) is a membrane-bound symporter that mediates the secondary active influx of sodium, potassium, and chloride ions across the plasma membrane of cells[1][4][8]. There are two principal isoforms: **NKCC1**, distributed widely in secretory tissues and important for fluid secretion, and **NKCC2**, which is predominantly expressed in the thick ascending limb of the loop of Henle in the kidney, where it is crucial for reabsorption of salt and maintaining electrolyte and water balance[1][7]. NKCC2 is a central target of loop diuretics (e.g., furosemide, bumetanide), which are used in the treatment of hypertension and fluid overload by inhibiting salt reabsorption and increasing diuresis[5][6][8]. Dysfunction or inhibition of these cotransporters is linked to disorders such as Bartter syndrome and has important roles in blood pressure regulation, electrolyte homeostasis, and kidney disease pathophysiology[1][7][8]. Key facts: - Canonical transporter stoichiometry is 1Na⁺ : 1K⁺ : 2Cl⁻ per cycle[1][8]. - NKCC isoforms are regulated through phosphorylation and alternative splicing[1][7]. - Drugs targeting NKCC2 are widely used diuretics for cardiovascular and renal diseases[5][6][3]. - Genetic mutations in NKCC2 (SLC12A1) can cause Bartter syndrome type I, a salt-wasting nephropathy[7].

Other names

Na–K–Cl cotransporterNKCC1NKCC2SLC12A2 (gene for NKCC1)SLC12A1 (gene for NKCC2)Sodium–potassium–chloride symporter

Inhibition of NKCC2 by loop diuretics reduces sodium, potassium, and chloride reabsorption in the thick ascending limb of the loop of Henle, leading to increased urinary excretion of these ions and water, thus lowering blood volume and blood pressure[5][6][3][1].